D2C7 for Adult Patients With Recurrent Malignant Glioma

Last updated: October 20, 2026
Sponsor: Darell Bigner
Overall Status: Completed

Phase

1

Condition

Brain Cancer

Gliomas

Astrocytoma

Treatment

D2C7-IT

Clinical Study ID

NCT02303678
Pro00053325
  • Ages > 18
  • All Genders

Study Summary

This is a Phase I study to determine the maximum tolerated dose (MTD) and/or recommended phase II dose of D2C7-IT (D2C7 Immunotoxin) when delivered intratumorally by convection-enhanced delivery (CED) to recurrent World Health Organization (WHO) grade III and IV malignant glioma patients, and/or to determine what dose will be considered in a Phase II trial. Patients with recurrent WHO grade III and IV malignant glioma who meet eligibility criteria will be enrolled into the study. Immediately following the stereotactically-guided tumor biopsy conducted as standard of care, up to three additional core biopsies will be obtained for molecular genetic testing. After these biopsies are obtained, subjects will have up to 2 catheters inserted. If the biopsy indicates a proven diagnosis of recurrent malignant glioma (diagnosis results are typically received within 24-48 hours following biopsy), the investigators will proceed with the D2C7-IT infusion. If no tumor is identified, the catheters will be removed. A continuous intratumoral infusion of D2C7-IT will be administered over 72 hours while in the hospital.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patients must have a recurrent supratentorial WHO grade III or IV malignant gliomabased on imaging studies;

  • Prior histopathology consistent with a supratentorial WHO grade III or IV malignantglioma;

  • Following biopsy, prior to administration of D2C7-IT, the presence of recurrenttumor must be confirmed by histopathological analysis;

  • Age ≥ 18 years of age;

  • Karnofsky Performance Status (KPS) ≥ 70%;

  • Laboratory Values:

  • Platelet count ≥ 100,000/µl unsupported is necessary for eligibility on thestudy; however, because of risks of intracranial hemorrhage with catheterplacement, platelet count ≥ 125,000/µl is required for the patient to undergobiopsy and catheter insertion, which can be attained with the help of platelettransfusion;

  • Hemoglobin ≥ 9 gm/dL prior to biopsy;

  • Absolute neutrophil count (ANC) ≥ 1000 cells/mm3 prior to biopsy;

  • Serum creatinine ≤ 1.5 x the upper limit of normal (ULN) prior to biopsy;

  • Liver Function: Total bilirubin ≤ 1.5 x ULN prior to biopsy (Exception: Patienthas known Gilbert's Syndrome or patient has suspected Gilbert's Syndrome, forwhich additional lab testing of direct and/or indirect bilirubin supports thisdiagnosis. In these instances, a total bilirubin of ≤ 3.0 x ULN isacceptable.); AST (aspartate aminotransferase)/ALT (alanine aminotransferase) ≤ 2.5 x the ULN prior to biopsy;

  • Prothrombin (PT) and activated Partial Thromboplastin Time (aPTT) ≤ 1.2 x upperlimit of normal (ULN) prior to biopsy. Patients with prior history ofthrombosis/embolism are allowed to be on anticoagulation, understanding thatanti-coagulation will be held in the peri-operative period per theneurosurgical team's recommendations. Low molecular weight heparin (LMWH) ispreferred. If a patient is on warfarin, the international normalized ratio (INR) is to be obtained and value should be below 2.0 prior to biopsy;

  • Ability to comply with study and follow-up procedures;

  • If the patient is a sexually active female of child bearing potential, whosepartner is male, or if the patient is a sexually active male, whose partner isa female of child bearing potential, the patient must agree to use appropriatecontraceptive measures for the duration of the treatment of the tumor and for 6months afterwards as stated in the informed consent. Female patients of childbearing potential must have a negative serum pregnancy test at the time ofscreening and within 48 hours of starting the D2C7-IT infusion

  • Patients will sign an IRB-approved informed consent form prior to any study-relatedprocedures.

  • Able to undergo brain MRI with and without contrast.

Exclusion

Exclusion Criteria:

  • Prior, unrelated malignancy requiring current active treatment with the exception ofcervical carcinoma in situ and adequately treated basal cell or squamous cellcarcinoma of the skin;

  • Pregnant or breastfeeding;

  • Patients with contrast-enhancing tumor component crossing the midline, activelygrowing multi-focal tumor, infratentorial tumor or extensive tumor dissemination (subependymal or leptomeningeal);

  • Patients with clinically significant increased intracranial pressure (e.g.,impending herniation), uncontrolled seizures, or requirement for immediatepalliative treatment;

  • Patients with a known severe allergy to Gadolinium-DTPA. Patients with mildallergies (e.g., rash only) will be pretreated with acetaminophen anddiphenhydramine prior to injection of the contrast agent;

  • Unstable systemic disease in the opinion of the treating physician, for exampleactive infection requiring IV antibiotics;

  • Patients on greater than 4mg per day of dexamethasone within the 2 weeks prior toadmission for D2C7-IT infusion;

  • Patients with worsening steroid myopathy (history of gradual progression ofbilateral proximal muscle weakness, and atrophy of proximal muscle groups);

  • Patients who have not completed standard of care treatment prior to participation inthis trial, i.e. surgical procedure and radiation therapy (at least 59 Gy). Note: Iftumor is unmethylated, patients are not mandated to have received chemotherapy priorto participation in this trial. However, if tumor is methylated, patients must havereceived at least one chemotherapy regimen prior to participation in this trial.

  • Less than 12 weeks from radiation therapy, unless progressive disease outside of theradiation field or 2 progressive scans at least 4 weeks apart or histopathologicconfirmation;

  • Treated with immunotherapeutic agents within 4 weeks before enrollment, unless thepatient has recovered from the expected toxic effects of such therapy;

  • Treated with antiangiogenic agents (like bevacizumab) within 4 weeks before biopsy;

  • Treated with alkylating agents within 4 weeks before enrollment (6 weeks fornitrosoureas) or treated within 1 week before enrollment with daily or metronomicchemotherapy, unless the patient has recovered from the expected toxic effects ofsuch therapy;

  • Prior chemotherapy (non-alkylating agents) within 2 weeks before enrollment, unlessthe patient has recovered from the expected toxic effects of such therapy.

Study Design

Total Participants: 81
Treatment Group(s): 1
Primary Treatment: D2C7-IT
Phase: 1
Study Start date:
May 05, 2015
Estimated Completion Date:
March 25, 2024

Study Description

This is a Phase I study to determine the maximum tolerated dose (MTD) of D2C7-IT, when delivered intratumorally by convection-enhanced delivery (CED) following confirmatory diagnostic biopsy in recurrent World Health Organization (WHO) grade III and IV malignant glioma patients, and/or to determine what dose will be considered in a phase II trial. The patient will remain in the hospital during the entire infusion. At the completion of the infusion, the catheters will be removed within 6 hours and a CT scan will be obtained after the catheters are pulled. The patient will be observed in hospital for a minimum of another 6 hours.

A two-stage continual reassessment method (CRM) design will be used to determine the MTD of D2C7-IT where the first stage involves dose escalation in successive patients until an initial dose-limiting toxicity (DLT) is observed. Cohorts of 2 patients will be accrued to this study within both stages of the trial. The first patient of each cohort will be observed through the completion of the D2C7-IT infusion, before additional patients in that cohort are treated. Once the optimal dose level of D2C7-IT is determined (dose escalation completed), a total of 27 recurrent patients with WHO grade IV malignant glioma patients will be treated at that dose level as a dose expansion cohort.

Following D2C7-IT infusion, subjects will be evaluated in clinic at 2 weeks for adverse events and followed at 4 and 8 weeks and every 8 weeks thereafter until 48 weeks.

Connect with a study center

  • Preston Robert Tisch Brain Tumor Center at Duke

    Durham, North Carolina 27710
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.